Sigma-Tau's ACT combo protects patients from new malaria infections for two months
The results of two new large scale trials show that the combination of dihydroartemisinin and piperaquine protects patients against new infections for at least two months after treatment.
Developed by Italian drug company Sigma-Tau, the agent is effective against uncomplicated malaria in a way that is comparable to other artemisinin-based combination therapies and, according to the firm, was also very well tolerated with no significant side effects.
The results were presented at the 57th annual meeting of the American Society of Tropical Medicine & Hygiene held in New Orleans. Company chairman Claudio Cavazza, said the data suggest the new combination could become "the gold standard in malaria treatment in countries where drug-resistance has been observed with conventional antimalarials."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze